Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA.
OBJECTIVE
The aim of this study was to assess whether good EULAR response assessed at 3months may predict the achievement of low disease activity (LDA) at 1year in rheumatoid arthritis (RA) patients on treatment with certolizumab pegol (CZP).


METHODS
From the nationwide Italian registry, we analysed 278 RA patients (age 54.8±12years, duration of disease 9.8±8years, female 84%) initiating CZP as first line (68%) or≥second line (32%) of biological treatment because of their active disease. Assessment of disease activity was based on 28 joint Disease Activity Score (DAS28). A reduction of DAS28>1.2 (good EULAR response) was assessed at 3months, and the achievement of LDA (DAS28≤3.2) was evaluated at 1year. Multiple regression models were used to estimate predictors of early good EULAR response or LDA.


RESULTS
The percentages of patients attaining good EULAR response were 52% at 3, 65% at 6, and 66% at 12months. Furthermore, 51.2% (98/192) of the patients reached LDA at 12months. Patients taking CZP as first biological treatment had adjusted odds ratios (OR) of good EULAR response at 3months 6 folds higher than in those with≥1 prior biological drug (OR 6.7, 95% CI 1.97-23.1). While, the strongest variable correlating with 12months LDA was the achievement of good EULAR response at 3months (OR 11.3, 95% CI 13.1-34.8).


CONCLUSIONS
Our findings showed that attaining good EULAR response at 3months strongly predicted 1year LDA in RA patients treated with CZP in real-life settings.
Rheumatology unit, university of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy. Electronic address: florenzo.iannone@uniba.it.
Florenzo
F
Iannone
Rheumatology service DSS Casarano Gallipoli, ASL Lecce, Italy.
Giorgio
G
Carlino
Rheumatology unit, Ospedale G Pini, Milano, Italy.
Antonio
A
Marchesoni
Rheumatology unit, Ospedale Sacco, Milano, Italy.
Piercarlo
P
Sarzi-Puttini
Rheumatology unit, university of Brescia, Brescia, Italy.
Roberto
R
Gorla
Rheumatology unit, university of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy.
Giovanni
G
Lapadula
D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy*; D000068582:Certolizumab Pegol / Q000627:therapeutic use*; D015331:Cohort Studies; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D012042:Registries; D012044:Regression Analysis; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000068582:Certolizumab Pegol
Anti-TNF; EULAR response; GISEA; Registry